Drug intelligence / Profile preview

1805

Development stage: Unknown
Lead developer: Revolo Biotherapeutics

Overview

'1805' is a first-in-class immune-resetting therapy developed by Revolo Biotherapeutics (formerly Immune Regulation). It is currently in development for the treatment of rheumatoid arthritis and non-infectious uveitis, having completed Phase 2a studies and progressing to upcoming Phase 2 clinical trials. The drug aims to reset the immune system to address these conditions.

Beyond the preview

Go deeper on 1805.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1805.

Explore the full profile